Abstract: An electronic device may have a display with touch sensors. One or more shielding layers may be interposed between the display and the touch sensors. The display may include transistors with gate conductors, a first planarization layer formed over the gate conductors, one or more contacts formed in a first source-drain layer within the first planarization layer, a second planarization layer formed on the first planarization layer, one or more data lines formed in a second source-drain layer within the second planarization layer, a third planarization layer formed on the second planarization layer, and a data line shielding structure formed at least partly in a third source-drain layer within the third planarization layer. The data line shielding structure may be a routing line, a blanket layer, a mesh layer formed in one or more metal layers, and/or a data line covering another data line.

Abstract: A strain sensor may have a conductive elastic yarn including a first fiber having a predetermined length and a shape of a fiber yarn and a second fiber having electrical conductivity and a sheet shape. The strain sensor may have a pair of wiring members electrically connected to both ends of the conductive elastic yarn. The conductive elastic yarn, with the second fiber wrapped around the first fiber, is twisted in a coil shape.

Abstract: A method for transmitting specific data whose data format is unknown at a relay from a first blockchain network to a second blockchain network via the relay is provided. The method includes steps of: the relay (a) in response to detecting that a blockchain communication message for transmitting the specific data from the first blockchain network following a first data format to the second blockchain network following a second data format is generated, generating a relay message including the blockchain communication message and verification information; and (b) transmitting the relay message to the second blockchain network, thereby instructing the second blockchain network to (i) verify the relay message by using the verification information included in the relay message and (ii) convert the specific data included in the relay message into the second data format to generate converted specific data and then transmit the converted specific data to a receiving party.

Abstract: The present invention relates to a composition, for prevention or treatment of cancer diseases, comprising CD8+ T cells activated by CD4+ T cell-derived extracellular vesicles as an active ingredient. It was found that the secretion of extracellular vesicles from cytokine-activated CD4+ T cells increases and the extracellular vesicles enhance proliferation and activity of CD8+ T cells to induce the death of cancer cells, thereby augmenting an anticancer effect. Thus, the present invention provides the CD8+ T cells activated by CD4+ T cell-derived extracellular vesicles as a pharmaceutical agent or an immunotherapeutic agent for cancer diseases, and a method for activating CD8+ T cells by using CD4+ T cell-derived extracellular vesicles to prepare CD8+ T cells showing excellent anticancer activity as described above.

Abstract: The present invention relates to a composition containing IL-2 or an expression promoter or activator thereof as an active ingredient for prevention or treatment of cancer disease. In the present invention, it was discovered that when treating cancer cells with IL-2, an anticancer effect was enhanced by inhibiting the secretion of cancer cell-derived exosomes and the expression of PD-L1 inducing immune escape of T cells. IL-2 was also discovered to effectuate the anticancer effect directly on cancer cells compared to conventional techniques exhibiting an immune anticancer effect by activating cytotoxic T cells. Thus, IL-2 or an expression promoter or activator thereof can be advantageously used in a composition for prevention or treatment of cancer diseases.

Abstract: The present invention relates to a method for screening a cytokine having anticancer activity that inhibits the exosome secretion or suppresses the expression of PD-L1, wherein a vector composed of gene encoding cytokine, linker domain, and transmembrane domain transforms into cancer cells, and cytokine exhibiting anticancer activity can be selected, and thus the selected cytokine is provided as a new anticancer agent. In addition, the present invention relates to composition for preventing or treating cancer diseases, the composition comprising IL-15, selected using the above-mentioned screening technique, or expression promoter or activator thereof as an active ingredient. In the present invention, it was found that treating cancer cells with IL-15 suppresses exosome secretion and the expression of PD-L1, and it was also found that the anticancer effect is directly exhibited on the cancer cells. Therefore, IL-15 or expression promoter or activator can be effectively used to prevent or treat cancer diseases.

Abstract: A method for equalizing SOCs of battery packs in an electric vehicle, may include acquiring, by a controller, SOC information of the battery packs from battery pack state information acquired by state detectors under predetermined conditions of the electric vehicle, determining, by the controller, an average SOC value of the battery packs based on acquired SOC values of the respective battery packs, determining, by the controller, at least one battery pack required to be discharged for equalization of the SOCs of the battery packs among all the battery packs based on the SOC values of the respective battery packs and the determined average SOC value of the battery packs, and operating, by the controller, an electric load connected to the at least one determined battery pack required to be discharged to discharge the at least one determined battery pack required to be discharged.

Abstract: An apparatus and a method for balancing batteries connected in parallel are provided. The apparatus collects States Of Charge (SOCs) of at least two or more battery packs, determines whether the at least two or more battery packs enter a balancing mode based on the collected SOCs of the at least two or more battery packs, determines a balancing control mode based on a vehicle state, when it is determined that the at least two or more battery packs enter the balancing mode, and controls a relay of at least one of the at least two or more battery packs depending on the determined balancing control mode to perform charging or discharging and performs balancing between the at least two or more battery packs.

Abstract: Example robotic process automation systems and methods are described. In one implementation, a processing system receives one or more configuration options for a Bot, where the configuration options are associated with a design specification for the Bot. The processing system generates the Bot using the configuration options and instantiates the Bot on the processing system. A workflow associated with the design specification is executed by the Bot.

Abstract: The present invention relates to a composition for preventing or treating cancer, the composition containing IL-2 surface expression-extracellular vesicles as an active ingredient. According to the present invention, immune cells, in which useful cytokines have been expressed on the cell surface, and extracellular vesicles, preferably small extracellular vesicles (sEV), which are derived from the immune cells and have useful cytokines expressed on the surface were prepared using a lentiviral vector containing a cytokine-linker-a PDGF receptor transmembrane domain, and it was found that the extracellular vesicles increased proliferation and activity of cytotoxic T cells thereby increasing anti-cancer immune efficacy. Thus, the extracellular vesicles having the efficacy can be usefully utilized as a pharmaceutical composition for preventing or treating cancer, a pharmaceutical composition for co-administration with an anticancer drug, or a composition for delivering a drug or a physiologically active material.

Abstract: The present invention relates to extracellular vesicles derived from ginger (Zingiber officinale) and a use thereof, and provides: extracellular vesicles which are derived from ginger and have anticancer activity, a pharmaceutical composition and a health functional food composition which is for preventing or treating cancer and contains the extracellular vesicles as an active ingredient. The ginger-derived extracellular vesicles can penetrate into cancer cells, have excellent anticancer activity, such as inhibiting the proliferation, infiltration and migration of cancer cells, and thus may be provided as an effective anticancer composition.

Abstract: A method for equalizing SOCs of battery packs in an electric vehicle, may include acquiring, by a controller, SOC information of the battery packs from battery pack state information acquired by state detectors under predetermined conditions of the electric vehicle, determining, by the controller, an average SOC value of the battery packs based on acquired SOC values of the respective battery packs, determining, by the controller, at least one battery pack required to be discharged for equalization of the SOCs of the battery packs among all the battery packs based on the SOC values of the respective battery packs and the determined average SOC value of the battery packs, and operating, by the controller, an electric load connected to the at least one determined battery pack required to be discharged to discharge the at least one determined battery pack required to be discharged.

Abstract: The present invention relates to a use of an endothelin receptor inhibitor for inhibiting exosome secretion or inhibiting PD-L1 expression. It was confirmed that the endothelin receptor inhibitor inhibits endothelin receptors, which are currently known as a target for anticancer drug development, to not only inhibit the secretion of cancer cell-derived exosomes, but also reduce the expression of PD-L1 in cells, and is thus effective for cancer treatment when used in combination with existing anticancer drugs or when used alone in the form of a drug. Accordingly, the present invention can be used in novel modes of anticancer drug development using drugs exhibiting immune-checkpoint inhibition effects and exosome secretion inhibition effects.

Abstract: Example robotic process automation systems and methods are described. In one implementation, a processing system receives a first automation scenario, where the first automation scenario is for execution by the processing system. The processing system identifies a list of plugins in the first automation scenario and identifies a version number associated with each of the plugins in the first automation scenario. Additionally, the processing system verifies the list of plugins and their associated version numbers. If the list of plugins and their associated version numbers are verified, the processing system builds a first virtual environment for the plugins in the first automation scenario.

Abstract: The present invention relates to a method for treating cancer and/or suppressing metastasis in a subject, the method comprising administering an effective amount of a composition to a subject in need thereof, the composition comprising a sulfonamide-based compound as an active ingredient.

Abstract: The present invention relates to a compound of dihydrophaseic acid 3?-O-beta-D-glucopyranoside for the prevention and treatment of osteoporosis. It was found that the D3G isolated from the Lycium root bark extract induces the activity of osteoblast differentiation while promoting the proliferation of pre-osteoblast, and promotes the bone remodeling by promoting the differentiation of both osteoblast and osteoclast when mixing and culturing pre-osteoblast which is the precursor of osteoblast, and monocyte which is the precursor of osteoclast. Therefore, the D3G of the present invention is expected to be useful as a pharmacological agent or functional food effective for the prevention and treatment of osteoporosis which is a disease caused by the abnormal balance of bone remodeling.

Abstract: The present disclosure relates to a composition for treating cancer and inhibiting cancer metastasis, which contains a sulfonamide derivative as an active ingredient. More specifically, the composition containing a sulfonamide derivative as an active ingredient may be provided as a cancer therapeutic agent or a cancer metastasis inhibitor since the sulfonamide derivative from which antibiotic susceptibility has been completely removed exhibits superior effect of inhibiting cancer cell multiplication and migration by effectively inhibiting the secretion of exosomes by cancer cells and exhibits no cytotoxicity to normal cells.

Abstract: A method of uploading and downloading data to an application server requested from a computing device, by a biometric information based authentication device which is connected to the computing device and interworks with a control server, is provided. The method includes detecting an upload request message which is transmitted from the computing device to the application server, extracting a first identifier included in the upload request message, outputting a first biometric information authentication result for input first biometric information, and transmitting upload authentication information comprising the first identifier, the first biometric information authentication result, and a first data encryption key to the control server.

Abstract: A method of providing a login to website requested from a computing device, by a biometric information based authentication device which interworks with a control server, is provided. The method includes detecting a login request message transmitted from the computing device to a website server providing the website, extracting login session information from the login request message, outputting an authentication result with respect to received biometric information, and transmitting authentication information comprising the login session information and the authentication result to the control server. The login session information is transmitted from the control server to the website server to determine, by the website server, the login allowance of the website.

Abstract: Example robotic process automation systems and methods are described. In one implementation, a processing system receives a first automation scenario, where the first automation scenario is for execution by the processing system. The processing system identifies a list of plugins in the first automation scenario and identifies a version number associated with each of the plugins in the first automation scenario. Additionally, the processing system verifies the list of plugins and their associated version numbers. If the list of plugins and their associated version numbers are verified, the processing system builds a first virtual environment for the plugins in the first automation scenario.